Dichlorphenamide
Based on 2 publication(s) in Google Scholar
Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research.
For research use only. We do not sell to patients.
- Purity: 98.49%
- CAS No.: 120-97-8
- Formula: C6H6Cl2N2O4S2
- Molecular Weight:305.16
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Dichlorphenamide
More
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male albino rabbits (approximately 2.5 kg)
-
Dosage:50 μL 10% aqueous solutions of dichlorphenamide sodium or 2 mg/kg, 6 mg/kg
-
Administration:Eye drop of 50 μL or Oral gavage of 2 mg/kg or 6 mg/kg, 5 hours
-
Result:Showed significant decrease in IOP at 30 min by instilling into eyes and decrease in IOP only at 1 h by orally after drug administration, and demonstrated that drug levels were significantly higher in the iris ciliary body and lower in the serum by instilling compared to oral administration.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 120-97-8
-
Appearance Solid
-
Molecular Weight 305.16
-
Formula C6H6Cl2N2O4S2
-
Color White to off-white
-
SMILES
O=S(C1=CC(Cl)=C(Cl)C(S(=O)(N)=O)=C1)(N)=O
-
Synonyms
Diclofenamide
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
EMBO Rep
2022 Jun 7;23(6):e53932. PMID: 35403787
Solvent & Solubility
DMSO : 100 mg/mL (327.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (556 KB)
- English - EN (556 KB)
- Français - FR (556 KB)
- Deutsch - DE (556 KB)
- Norwegian - NO (556 KB)
- Español - ES (556 KB)
- Swedish - SV (556 KB)
- Italian - IT (556 KB)
- Portuguese - PT (556 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kanski, J.J., Carbonic anhydrase inhibitors and osmotic agents in glaucoma. Carbonic anhydrase inhibitors. Br J Ophthalmol, 1968. 52(8): p. 642-3. [Content Brief]
[2]. Rucquoy, M. and L. Sorel, Diclofenamide in the treatment of therapy-resistant epilepsy. Acta Neurol Belg, 1978. 78(3): p. 174-82. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2770 mL | 16.3848 mL | 32.7697 mL | 81.9242 mL |
| 5 mM | 0.6554 mL | 3.2770 mL | 6.5539 mL | 16.3848 mL | |
| 10 mM | 0.3277 mL | 1.6385 mL | 3.2770 mL | 8.1924 mL | |
| 15 mM | 0.2185 mL | 1.0923 mL | 2.1846 mL | 5.4616 mL | |
| 20 mM | 0.1638 mL | 0.8192 mL | 1.6385 mL | 4.0962 mL | |
| 25 mM | 0.1311 mL | 0.6554 mL | 1.3108 mL | 3.2770 mL | |
| 30 mM | 0.1092 mL | 0.5462 mL | 1.0923 mL | 2.7308 mL | |
| 40 mM | 0.0819 mL | 0.4096 mL | 0.8192 mL | 2.0481 mL | |
| 50 mM | 0.0655 mL | 0.3277 mL | 0.6554 mL | 1.6385 mL | |
| 60 mM | 0.0546 mL | 0.2731 mL | 0.5462 mL | 1.3654 mL | |
| 80 mM | 0.0410 mL | 0.2048 mL | 0.4096 mL | 1.0241 mL | |
| 100 mM | 0.0328 mL | 0.1638 mL | 0.3277 mL | 0.8192 mL |